Hereditary non-polyposis colorectal cancer or Lynch syndrome: The gynaecological perspective

Current Opinion in Obstetrics and Gynecology

Volumn 21, Issue 1, 2009, Pages 31-38

  Manchanda, Ranjit ^a   Menon, Usha ^a   Michaelson Cohen, Rachel ^b   Beller, Uziel ^b   Jacobs, Ian ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Gynaecological cancer; HNPCC lynch syndrome; Microsatellite instability; Mismatch repair genes

Indexed keywords

ETHINYLESTRADIOL; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; NORGESTREL; ORAL CONTRACEPTIVE AGENT; PROGESTERONE;

CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; FAMILIAL CANCER; GENETIC ANALYSIS; HUMAN; HYSTERECTOMY; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; OVARY CANCER; PRIORITY JOURNAL; REVIEW; SALPINGOOOPHORECTOMY;

ADULT; CLINICAL PROTOCOLS; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; ENDOMETRIAL NEOPLASMS; FEMALE; GUIDELINES AS TOPIC; HUMANS; IMMUNOHISTOCHEMISTRY; MASS SCREENING; MICROSATELLITE INSTABILITY; MIDDLE AGED; OVARIAN NEOPLASMS; RISK ASSESSMENT;

EID: 59149099120     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/GCO.0b013e32831c844d     Document Type: Review

References (102)

1. Classics in oncology. Heredity with reference to carcinoma as shown by the study of the cases examined in the pathological laboratory of the University of Michigan, 1895-1913. By Aldred Scott Warthin. 1913. CA Cancer J Clin 1985; 35:348-359.
2. Lynch HT, Krush AJ. Cancer family 'G' revisited: 1895-1970. Cancer 1971; 27:1505-1511.
3. Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med 2003; 348:919-932.
4. Broaddus RR, Lynch PM, Lu KH, et al., Unusual tumors associated with the hereditary nonpolyposis colorectal cancer syndrome. Mod Pathol 2004; 17:981-989.
5. de la Chapelle A. The incidence of Lynch syndrome. Fam Cancer 2005; 4:233-237.
6. Hampel H, Frankel WL, Martin E, et al., Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 2005; 352:1851-1860.
7. Malander S, Rambech E, Kristoffersson U, et al., The contribution of the hereditary nonpolyposis colorectal cancer syndrome to the development of ovarian cancer. Gynecol Oncol 2006; 101:238-243.
8. Rubin SC, Blackwood MA, Bandera C, et al., BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing. Am J Obstet Gynecol 1998; 178:670-677.
9. Lu KH, Schorge JO, Rodabaugh KJ, et al., Prospective determination of prevalence of Lynch syndrome in young women with endometrial cancer. J Clin Oncol 2007; 25:5158-5164. Gives the prevalence of Lynch syndrome in women with endometrial cancer under the age of 50.
10. Berends MJ, Wu Y, Sijmons RH, et al., Toward new strategies to select young endometrial cancer patients for mismatch repair gene mutation analysis. J Clin Oncol 2003; 21:4364-4370.
11. Ollikainen M, Abdel-Rahman WM, Moisio AL, et al., Molecular analysis of familial endometrial carcinoma: a manifestation of hereditary nonpolyposis colorectal cancer or a separate syndrome? J Clin Oncol 2005; 23:4609 - 4616.
12. Vasen HF, Mecklin JP, Khan PM, et al., The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum 1991; 34:424-425.
13. Vasen HF, Watson P, Mecklin JP, et al., New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 1999; 116:1453-1456.
14. Umar A, Boland CR, Terdiman JP, et al., Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004; 96:261 -268.
15. Rodriguez-Bigas MA, Boland CR, Hamilton SR, et al., A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst 1997; 89:1758-1762.
16. Lindor NM, Rabe K, Petersen GM, et al., Lower cancer incidence in Amsterdam-l criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA 2005; 293:1979-1985.
17. Syngal S, Fox EA, Eng C, et al., Sensitivity and specificity of clinical criteria for hereditary nonpolyposis colorectal cancer associated mutations in MSH2 and MLH1. J Med Genet 2000; 37:641 -645.
18. Balmana J, Stockwell DH, Steyerberg EW, et al., Prediction of MLH1 and MSH2 mutations in Lynch syndrome. JAMA 2006; 296:1469-1478.
19. Lipton LR, Johnson V, Cummings C, et al., Refining the Amsterdam Criteria and Bethesda Guidelines: testing algorithms for the prediction of mismatch repair mutation status in the familial cancer clinic. J Clin Oncol 2004; 22:4934-4943.
20. Gruber SB. New developments in Lynch syndrome (hereditary nonpolyposis colorectal cancer) and mismatch repair gene testing. Gastroenterology 2006; 130:577-587.
21. Bellacosa A, Genuardi M, Anti M, et al., Hereditary nonpolyposis colorectal cancer: review of clinical, molecular genetics, and counseling aspects. Am J Med Genet 1996; 62:353-364.
22. Benatti P, Sassatelli R, Roncucci L, et al., Tumour spectrum in hereditary nonpolyposis colorectal cancer (HNPCC) and in families with 'suspected HNPCC'. A population-based study in northern Italy. Colorectal Cancer Study Group. Int J Cancer 1993; 54:371 -377.
23. Aarnio M, Sankila R, Pukkala E, et al., Cancer risk in mutation carriers of DNA- mismatch-repair genes. Int J Cancer 1999; 81:214-218.
24. Hendriks YM, Wagner A, Morreau H, et al., Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance. Gastroenterology 2004; 127:17-25.
25. Kastrinos F, Stoffel EM, Balmana J, et al., Phenotype comparison of MLH1 and MSH2 mutation carriers in a cohort of 1914 individuals undergoing clinical genetic testing in the United States. Cancer Epidemiol Biomarkers Prev 2008; 17:2044-2051.
26. Lin KM, Shashidharan M, Thorson AG, et al., Cumulative incidence of colorectal and extracolonic cancers in MLH1 and MSH2 mutation carriers of hereditary nonpolyposis colorectal cancer. J Gastrointest Surg 1998; 2:67- 71.
27. Vasen HF, Wijnen JT, Menko FH, et al., Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 1996; 110:1020-1027.
28. Carayol J, Khlat M, Maccario J, et al., Hereditary nonpolyposis colorectal cancer: current risks of colorectal cancer largely overestimated. J Med Genet 2002; 39:335-339.
29. Jenkins MA, Baglietto L, Dowty JG, et al., Cancer risks for mismatch repair gene mutation carriers: a population-based early onset case-family study. Clin Gastroenterol Hepatol 2006; 4:489-498.
30. Quehenberger F, Vasen HF, van Houwelingen HC. Risk of colorectal and endometrial cancer for carriers of mutations of the hMLH1 and hMSH2 gene: correction for ascertainment. J Med Genet 2005; 42:491 -496. Provides cancer penetrance estimates after correcting for ascertainment.
31. Watson P, Lynch HT. Cancer risk in mismatch repair gene mutation carriers. Fam Cancer 2001; 1:57-60.
32. Cederquist K, Emanuelsson M, Wiklund F, et al., Two Swedish founder MSH6 mutations, one nonsense and one missense, conferring high cumulative risk of Lynch syndrome. Clin Genet 2005; 68:533-541.
33. Wagner A, Hendriks Y, Meijers-Heijboer EJ, et al., Atypical HNPCC owing to MSH6 germline mutations: analysis of a large Dutch pedigree. J Med Genet 2001; 38:318-322.
34. Plaschke J, Engel C, Kruger S, et al., Lower incidence of colorectal cancer and later age of disease onset in 27 families with pathogenic MSH6 germline mutations compared with families with MLH1 or MSH2 mutations: the German Hereditary Nonpolyposis Colorectal Cancer Consortium. J Clin Oncol 2004; 22:4486-4494.
35. Buttin BM, Powell MA, Mutch DG, et al., Penetrance and expressivity of MSH6 germline mutations in seven kindreds not ascertained by family history. Am J Hum Genet 2004; 74:1262-1269.
36. Vasen HF, Watson P, Mecklin JP, et al., The epidemiology of endometrial cancer in hereditary nonpolyposis colorectal cancer. Anticancer Res 1994; 14 (4B):1675-1678.
37. Dunlop MG, Farrington SM, Carothers AD, et al., Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet 1997; 6:105-110.
38. Green J, O'Driscoll M, Barnes A, et al., Impact of gender and parent of origin on the phenotypic expression of hereditary nonpolyposis colorectal cancer in a large Newfoundland kindred with a common MSH2 mutation. Dis Colon Rectum 2002; 45:1223-1232.
39. Brown GJ, St John DJ, Macrae FA, et al., Cancer risk in young women at risk of hereditary nonpolyposis colorectal cancer: implications for gynecologic surveillance. Gynecol Oncol 2001; 80:346-349.
40. Hendriks YM, de Jong AE, Morreau H, et al., Diagnostic approach and management of Lynch syndrome (hereditary nonpolyposis colorectal carcinoma): a guide for clinicians. CA Cancer J Clin 2006; 56:213-225.
41. Vasen HF, Stormorken A, Menko FH, et al., MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families. J Clin Oncol 2001; 19:4074 - 4080.
42. Lu KH, Dinh M, Kohlmann W, et al., Gynecologic cancer as a 'sentinel cancer' for women with hereditary nonpolyposis colorectal cancer syndrome. Obstet Gynecol 2005; 105:569-574.
43. Broaddus RR, Lynch HT, Chen LM, et al., Pathologic features of endometrial carcinoma associated with HNPCC: a comparison with sporadic endometrial carcinoma. Cancer 2006; 106:87-94.
44. Watson P, Butzow R, Lynch HT, et al., The clinical features of ovarian cancer in hereditary nonpolyposis colorectal cancer. Gynecol Oncol 2001; 82:223-228.
45. Schmeler KM, Lynch HT, Chen LM, et al., Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 2006; 354:261 -269.
46. Crijnen TE, Janssen-Heijnen ML, Gelderblom H, et al., Survival of patients with ovarian cancer due to a mismatch repair defect. Fam Cancer 2005; 4:301 - 305.
47. Myrhoj T, Bisgaard ML, Bernstein I, et al., Hereditary nonpolyposis colorectal cancer: clinical features and survival. Results from the Danish HNPCC register. Scand J Gastroenterol 1997; 32:572-576.
48. Watson P, Lin KM, Rodriguez-Bigas MA, et al., Colorectal carcinoma survival among hereditary nonpolyposis colorectal carcinoma family members. Cancer 1998; 83:259-266.
49. Sankila R, Aaltonen LA, Jarvinen HJ, et al., Better survival rates in patients with MLH1-associated hereditary colorectal cancer. Gastroenterology 1996; 110:682-687.
50. Lynch HT, Albano W, Recerbaren J, et al., Prolonged survival as a component of a hereditary breast and nonpolyposis colon cancer. Med Hypotheses 1981; 7:1201-1209.
51. Boks DE, Trujillo AP, Voogd AC, et al., Survival analysis of endometrial carcinoma associated with hereditary nonpolyposis colorectal cancer. Int J Cancer 2002; 102:198-200.
52. Lindor NM, Petersen GM, Hadley DW, et al., Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA 2006; 296:1507-1517.
53. Lynch HT, Boland CR, Gong G, et al., Phenotypic and genotypic heterogeneity in the Lynch syndrome: diagnostic, surveillance and management implications. Eur J Hum Genet 2006; 14:390-402.
54. Vasen HF, Boland CR. Progress in genetic testing, classification, and identification of Lynch syndrome. JAMA 2005; 293:2028-2030.
55. Vasen HF, Hendriks Y, de Jong AE, et al., Identification of HNPCC by molecular analysis of colorectal and endometrial tumors. Dis Markers 2004; 20:207-213.
56. Chen S, Watson P, Parmigiani G. Accuracy of MSI testing in predicting germline mutations of MSH2 and MLH1: a case study in Bayesian meta-analysis of diagnostic tests without a gold standard. Biostatistics 2005; 6:450-464.
57. Kuismanen SA, Moisio AL, Schweizer P, et al., Endometrial and colorectal tumors from patients with hereditary nonpolyposis colon cancer display different patterns of microsatellite instability. Am J Pathol 2002; 160:1953-1958. The study shows molecular differences in endometrial and colorectal tumors.
58. Macdonald ND, Salvesen HB, Ryan A, et al., Molecular differences between RER+ and RER- sporadic endometrial carcinomas in a large population- based series. Int J Gynecol Cancer 2004; 14:957-965.
59. de Leeuw WJ, Dierssen J, Vasen HF, et al., Prediction of a mismatch repair gene defect by microsatellite instability and immunohistochemical analysis in endometrial tumours from HNPCC patients. J Pathol 2000; 192:328- 335.
60. Hampel H, Frankel W, Panescu J, et al., Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res 2006; 66:7810-7817.
61. Kaneki E, Oda Y, Ohishi Y, et al., Frequent microsatellite instability in synchronous ovarian and endometrial adenocarcinoma and its usefulness for differential diagnosis. Hum Pathol 2004; 35:1484-1493.
62. Wijnen JT, Vasen HF, Khan PM, et al., Clinical findings with implications for genetic testing in families with clustering of colorectal cancer. N Engl J Med 1998; 339:511-518.
63. Chen S, Wang W, Lee S, et al., Prediction of germline mutations and cancer risk in the Lynch syndrome. JAMA 2006; 296:1479-1487.
64. Balaguer F, Balmana J, Castellvi-Bel S, et al., Validation and extension of the PREMM1,2 model in a population-based cohort of colorectal cancer patients. Gastroenterology 2008; 134:39-46. Risk prediction model for HNPCC/Lynch syndrome.
65. Barnetson RA, Tenesa A, Farrington SM, et al., Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. N Engl J Med 2006; 354:2751-2763.
66. Marroni F, Pastrello C, Benatti P, et al., A genetic model for determining MSH2 and MLH1 carrier probabilities based on family history and tumor microsatellite instability. Clin Genet 2006; 69:254-262.
67. Balmana J, Steyerberg EW, Syngal S. Risk quantification for carrying mutations in Lynch syndrome genes. ASCO Educational Book 2008; 2008. pp. 59-64. http://edbook.ascopubs.org/cgi/content/abstract/2008/1/59. A review comparing different models in Lynch syndrome.
68. Balmana J, Balaguer F, Castellvi-Bel S, et al., Comparison of predictive models, clinical criteria and molecular tumor screening for the identification of patients with Lynch syndrome in a population-based cohort of colorectal cancer patients. J Med Genet 2008; 45:557-563.
69. Dove-Edwin I, Boks D, Goff S, et al., The outcome of endometrial carcinoma surveillance by ultrasound scan in women at risk of hereditary nonpolyposis colorectal carcinoma and familial colorectal carcinoma. Cancer 2002; 94:1708-1712.
70. Rijcken FE, Mourits MJ, Kleibeuker JH, et al., Gynecologic screening in hereditary nonpolyposis colorectal cancer. Gynecol Oncol 2003; 91:74-80.
71. Renkonen-Sinisalo L, Butzow R, Leminen A, et al., Surveillance for endometrial cancer in hereditary nonpolyposis colorectal cancer syndrome. Int J Cancer 2007; 120:821 -824. Series describing performance of ultrasound scan and endometrial sampling in screening of women with Lynch syndrome.
72. Lecuru F, Metzger U, Scarabin C, et al., Hysteroscopic findings in women at risk of HNPCC. Results of a prospective observational study. Fam Cancer 2007; 6:295-299. Series describing performance of hysteroscopy and endometrial sampling in screening of women with Lynch syndrome.
73. Lecuru F, Le Frere Belda MA, Bats AS, et al., Performance of office hysteroscopy and endometrial biopsy for detecting endometrial disease in women at risk of human nonpolyposis colon cancer: a prospective study. Int J Gynecol Cancer 2008. [Epub ahead of print] doi:10.1111/J.1525-1438.2007.01183.x Series describing performance of hysteroscopy and endometrial sampling in screening of women with Lynch syndrome.
74. Lu HK, Broaddus RR. Gynecologic cancers in Lynch syndrome/HNPCC. Fam Cancer 2005; 4:249-254.
75. Vasen HF, Moslein G, Alonso A, et al., Guidelines for the clinical management of Lynch syndrome (hereditary nonpolyposis cancer). J Med Genet 2007; 44:353-362.
76. Dijkhuizen FP, Mol BW, Brolmann HA, et al., The accuracy of endometrial sampling in the diagnosis of patients with endometrial carcinoma and hyperplasia: a meta-analysis. Cancer 2000; 89:1765-1772.
77. Giusa-Chiferi MG, Goncalves WJ, Baracat EC, et al., Transvaginal ultrasound, uterine biopsy and hysteroscopy for postmenopausal bleeding. Int J Gynaecol Obstet 1996; 55:39-44.
78. Gordon SJ, Westgate J. The incidence and management of failed Pipelle sampling in a general outpatient clinic. Aust N Z J Obstet Gynaecol 1999; 39:115-118.
79. Hewitt MJ, Wood N, Quinton ND, et al., The detection of microsatellite instability in blind endometrial samples: potential novel screening tool for endometrial cancer in women from hereditary nonpolyposis colorectal cancer families? Int J Gynecol Cancer 2006; 16:1393-1400.
80. Ichikawa Y, Tsunoda H, Takano K, et al., Microsatellite instability and immunohistochemical analysis of MLH1 and MSH2 in normal endometrium, endometrial hyperplasia and endometrial cancer from a hereditary nonpolyposis colorectal cancer patient. Jpn J Clin Oncol 2002; 32:110-112.
81. Skates SJ, Menon U, MacDonald N, et al., Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women. J Clin Oncol 2003; 21 (10 Suppl):206-210.
82. Menon U, Skates SJ, Lewis S, et al., Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer. J Clin Oncol 2005; 23:7919-7926.
83. Kwon JS, Sun CC, Peterson SK, et al., Cost-effectiveness analysis of prevention strategies for gynecologic cancers in Lynch syndrome. Cancer 2008; 113:326-335. Recent cost-effectiveness analysis in managing patients with Lynch syndrome.
84. Finch A, Beiner M, Lubinski J, et al., Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA 2006; 296:185-192.
85. Casey MJ, Synder C, Bewtra C, et al., Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations. Gynecol Oncol 2005; 97:457-467.
86. Rebbeck TR, Lynch HT, Neuhausen SL, et al., Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002; 346:1616 - 1622.
87. Pistorius S, Kruger S, Hohl R, et al., Occult endometrial cancer and decision making for prophylactic hysterectomy in hereditary nonpolyposis colorectal cancer patients. Gynecol Oncol 2006; 102:189-194.
88. Guillem JG, Wood WC, Moley JF, et al., ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. J Clin Oncol 2006; 24:4642-4660.
89. Lamb JD, Garcia RL, Goff BA, et al., Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy. Am J Obstet Gynecol 2006; 194:1702-1709.
90. Rocca WA, Grossardt BR, de Andrade M, et al., Survival patterns after oophorectomy in premenopausal women: a population-based cohort study. Lancet Oncol 2006; 7:821 -828.
91. Madalinska JB, Hollenstein J, Bleiker E, et al., Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer. J Clin Oncol 2005; 23:6890-6898.
92. McLaughlin JR, Risch HA, Lubinski J, et al., Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet Oncol 2007; 8:26-34.
93. Horn LC, Schnurrbusch U, Bilek K, et al., Risk of progression in complex and atypical endometrial hyperplasia: clinicopathologic analysis in cases with and without progestogen treatment. Int J Gynecol Cancer 2004; 14:348-353.
94. Kim YB, Holschneider CH, Ghosh K, et al., Progestin alone as primary treatment of endometrial carcinoma in premenopausal women. Report of seven cases and review of the literature. Cancer 1997; 79:320-327.
95. Shoupe D, Meme D, Mezrow G, et al., Prevention of endometrial hyperplasia in postmenopausal women with intrauterine progesterone. N Engl J Med 1991; 325:1811-1812.
96. Varila E, Wahlstrom T, Rauramo I. A 5-year follow-up study on the use of a levonorgestrel intrauterine system in women receiving hormone replacement therapy. Fertil Steril 2001; 76:969-973.
97. Gardner FJ, Konje JC, Abrams KR, et al., Endometrial protection from tamoxifen-stimulated changes by a levonorgestrel-releasing intrauterine system: a randomised controlled trial. Lancet 2000; 356:1711-1717.
98. Randall TC, Kurman RJ. Progestin treatment of atypical hyperplasia and well differentiated carcinoma of the endometrium in women under age 40. Obstet Gynecol 1997; 90:434-440.
99. Giannopoulos T, Butler-Manuel S, Tailor A. Levonorgestrel-releasing intrauterine system (LNG-IUS) as a therapy for endometrial carcinoma. Gynecol Oncol 2004; 95:762-764.
100. Jones K, Georgiou M, Hyatt D, et al., Endometrial adenocarcinoma following the insertion of a Mirena IUCD. Gynecol Oncol 2002; 87:216-218.
101. Dhar KK, NeedhiRajan T, Koslowski M, et al., Is levonorgestrel intrauterine system effective for treatment of early endometrial cancer? Report of four cases and review of the literature. Gynecol Oncol 2005; 97:924-927.
102. Hormone therapy in preventing endometrial carcinogenesis (cancer) in women with a genetic risk for hereditary nonpolyposis colon cancer. Available http://clinicaltrials.gov/ct/show/NCT00033358.